(Image generated using AI)

Albertans living with pulmonary arterial hypertension (PAH) will now have access to a groundbreaking treatment at no cost through Alberta’s Specialized High Cost Drug Program.

The Alberta government announced that Sotatercept, also known by the brand name Winrevair, has been added to provincial coverage for eligible patients. The medication is the first treatment for pulmonary arterial hypertension that targets the underlying biological cause of the disease rather than focusing solely on symptom management.

Pulmonary arterial hypertension is a rare and progressive condition that causes high blood pressure in the arteries of the lungs. The disease places increasing strain on the right side of the heart and can eventually lead to heart failure. While there is currently no cure, new treatment options have offered hope for improved outcomes and quality of life.

According to the province, pulmonary arterial hypertension affects approximately seven to eight Canadians per 100,000 people, including an estimated 270 Albertans. Although the disease can affect individuals of any age or background, women are diagnosed at roughly twice the rate of men.

Alberta Minister of Primary and Preventative Health Services Justin Wright said the new coverage will help improve access to a treatment that has shown promising results for patients living with the condition.

“Pulmonary arterial hypertension is a serious and disabling disease that can dramatically affect a person’s quality of life and place significant strain on families and caregivers,” Wright said. “This new coverage gives Albertans living with this condition access to a groundbreaking treatment that offers hope, improved quality of life and the opportunity to spend more time doing things they love.”

Medical experts have also welcomed the announcement.

Dr. Mitesh Thakrar, a pulmonary hypertension physician at the Peter Lougheed Centre and a board director with the Pulmonary Hypertension Association of Canada, said patients in Alberta have already experienced significant benefits from the medication.

“We have seen the immense benefits of this medication,” Thakrar said. “It is our hope that many patients will have significant and sustained improvements in their disease and quality of life and ability to participate more fully in everyday activities.”

Health Canada has approved Sotatercept for use in Canada, and pricing negotiations were completed through the pan-Canadian Pharmaceutical Alliance. Eligible patients will receive the medication alongside other therapies currently used to manage pulmonary arterial hypertension.

The Specialized High Cost Drug Program, administered by Acute Care Alberta, provides full coverage for eligible medications used to treat rare and complex conditions, including pulmonary arterial hypertension, organ transplant needs and cystic fibrosis.

Provincial officials say the addition of Sotatercept represents another step toward improving access to specialized treatments for Albertans living with serious and life-altering illnesses.

For more information about specialized drug and drug programs available for Albertans, visit the Government of Alberta website at www.alberta.ca/specialized-drug-benefits.

Information for this article was sourced from the Government of Alberta website.